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1  | INTRODUC TION
Suboptimal health status (SHS) is a physical state between health and 
disease and is characterized by the symptoms of health complaints, 
general weakness and low energy within a period of 3 months.1 
A comprehensive Suboptimal Health Status Questionnaire-25 
(SHSQ-25) was used to assess SHS, with the SHSQ-25 accounting 
for the multidimensionality of SHS by assessing the following: (a) fa-
tigue, (b) the cardiovascular system, (c) the digestive tract, (d) the 
immune system and (e) mental status.2 To date, the SHSQ-25 has 
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Abstract
Suboptimal health status (SHS), a physical state between health and disease, is a sub-
clinical and reversible stage of chronic disease. Previous studies have shown altera-
tions in the intestinal microbiota in patients with some chronic diseases. This study 
aimed to investigate the association between SHS and intestinal microbiota in a case-
control study with 50 SHS individuals and 50 matched healthy controls. Intestinal 
microbiota was analysed by MiSeq 250PE. Alpha diversity of intestinal microbiota in 
SHS individuals was higher compared with that of healthy controls (Simpson index, 
W = 2238, P = .048). Beta diversity was different between SHS and healthy controls 
(P = .018). At the phylum level, the relative abundance of Verrucomicrobia was higher 
in the SHS group than that in the controls (W = 2201, P = .049). Compared with 
that of the control group, nine genera were significantly higher and five genera were 
lower in abundance in the SHS group (all P < .05). The intestinal microbiota, analysed 
by a random forest model, was able to distinguish individuals with SHS from the con-
trols, with an area under the curve of 0.79 (95% confidence interval: 0.77-0.81). We 
demonstrated that the alteration of intestinal microbiota occurs with SHS, an early 
stage of disease, which might shed light on the importance of intestinal microbiota in 
the primary prevention of noncommunicable chronic diseases.
K E Y W O R D S
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been validated in various populations, including Chinese,3 African4 
and European populations.5 Although several items of SHS are sim-
ilar to some diseases, SHS cannot reach the diagnosable condition 
of any current defined diseases. SHS is not a disease state, but sev-
eral studies have suggested that SHS, as an overall assessment of 
human body, might precede the occurrence of noncommunicable 
chronic diseases (NCDs), including type 2 diabetes mellitus (T2DM), 
cardiovascular diseases and hypertension.3-6 A cross-sectional study 
conducted among workers in urban Beijing demonstrated that SHS 
was associated with cardiovascular risk factors.6 In Russia, a com-
munity-based cross-sectional study showed that SHS was related 
to endothelial dysfunction, suggesting that the integration of SHS 
and endothelial dysfunction can be applied to the elevated risk of 
cardiovascular diseases.5 In Ghana, a cross-sectional study demon-
strated that SHS might be involved in the development of T2DM.4 In 
a cross-sectional study of Chinese students, SHS was shown to be 
correlated with stress management, psychological states and physi-
cal activity.7 More recently, Anto et al8 found that high SHS score is 
associated with increased incidence of preeclampsia.
In China, due to modern lifestyles, increased work pressures, 
changes in diet and other factors, the prevalence of chronic diseases 
such as hypertension, heart disease, stroke, cancer, chronic obstruc-
tive pulmonary disease and diabetes is increasing.9 As a subclinical 
and reversible stage of chronic disease, SHS might play a very im-
portant role in the pathogenesis of chronic diseases.2 The aetiol-
ogy and mechanism of SHS are still poorly understood, and SHS is 
diagnosed based on subjective questionnaires and lacks objective 
biomarkers. Shortened relative telomere length, N-glycosylation and 
high levels of plasma cortisol were associated with SHS, suggesting 
that objective biomarkers have the potential to diagnose SHS.10-12 
Therefore, novel diagnostic markers based on objective measure-
ments are urgently needed.
In recent years, many studies have shown that intestinal micro-
biota play important roles in host health,13 as well as the immune 
system,14,15 nervous system,16 digestive system17 and cardiovascu-
lar system,18 all of which are components of SHS.2 Emerging evi-
dence suggests a link between the intestinal microbiota and various 
diseases, such as atherosclerosis,19,20 hypertension,21 T2DM22 and 
acquired immune deficiency syndrome.23 This association between 
microbiota and diseases was also validated through faecal transfer 
experiments.24-26 Furthermore, altered gut microbiota was observed 
in patients suffering from chronic fatigue syndrome (CFS), a disease 
resembling SHS.27,28 Fremont et al27 reported that intestinal mi-
crobiota is altered in myalgic encephalomyelitis/CFS patients from 
Belgium and Norway. Giloteaux et al28 found dysbiosis and translo-
cation of the intestinal microbiota in CFS. Because of the association 
between intestinal microbiota and NCDs, together with SHS as an 
early stage of NCDs, we hypothesized that the alternation of intes-
tinal microbiota might occur in SHS patients and that the interaction 
might increase the incidence of NCDs. In this study, we attempted to 
profile microbiota composition to identify novel bacteria associated 
with SHS.
2  | MATERIAL S AND METHODS
2.1 | Study population and design
Previously, we conducted a cross-sectional survey among under-
graduates at Weifang University, which is located in Shandong 
Province, China, in November 2017. In total, 5219 participants com-
pleted the questionnaire, of which 442 (8.50%) were considered 
suffering from SHS.29 Among these undergraduates, 50 cases and 
50 controls were included in this case-control study. All students 
attended a standardized examination protocol in Weifang Hospital, 
including an interview about the history of previous diseases, fam-
ily income, physical activity, smoking status and history of drinking. 
They received a blood biochemical examination and were asked to 
complete the SHSQ-25. SHSQ-25 includes 25 items: (a) item 1 to 6 
and item 8 to 10 are used to measure symptoms of fatigue; (b) item 
18 to 24 are used to measure symptoms of mental status; (c) item 11 
to 13 are used to measure symptoms of the cardiovascular system; 
(d) item 7, 17 and 25 are used to measure symptoms of immune sys-
tem; (e) item 14 to 16 are used to measure symptoms of the digestive 
tract (Table S1).2 Participants were enrolled if they met the following 
inclusion criteria: (a) signed informed consent; and (b) a completed 
questionnaire. They were excluded if they met the following exclu-
sion criteria: (a) a history of somatic or psychiatric abnormalities; (b) a 
history of mental illness or drug abuse; and (c) a history of antibiotic 
consumption in the previous 2 months. After enrolment, propensity 
score matching was used to match a subset of 50 SHS cases (SHS 
score ≥35) to a subset of 50 ideal healthy controls (SHS score <35) 
by age, gender and body mass index (BMI). The score was calculated 
from the SHSQ-25. The details of SHSQ-25 and the characteristics 
of the subjects between SHS group and control group are shown in 
Tables 1 and S2.
2.2 | Faecal sample collection and DNA extraction
Stool samples were obtained through a specimen collection kit and 
immediately stored at −80°C. Bacterial DNA was extracted at the 
Beijing Municipal Key Laboratory of Clinical Epidemiology using a 
TIANGEN kit based on the manufacturer's recommendations. The 
concentration and purity were evaluated using a Nanodrop® spectro-
photometer (Thermo Scientific). Extracted DNA was stored at −80°C.
2.3 | DNA sequencing of the 16S rRNA gene
The V4 region of the bacterial 16S rRNA gene was ampli-
fied from extracted faecal DNA through degenerate primers 
(515F/806R: forward GTGCCAGCMGCCGCGGTAA, reverse 
GGACTACHVGGGTWTCTAAT). The amplicons were purified 
and quantified, according to manufacturer's protocols by Beijing 
Cheerland Biotech Co., Ltd, China. The Polymerase chain reaction 
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(PCR) amplification was carried out in a 20 μL reaction system con-
taining 4 μL 5× FastPfu Buffer, 2 μL 2.5 mmol L−1 dNTPs, 0.8 μL 
Forward Primer (5 μmol L−1), 0.8 μL Reverse Primer (5 μmol L−1), 
0.4 μL FastPfu Polymerase DNA, 10 ng Template DNA and sup-
plementary distillation-distillation H2O (Cheerland Biotech). The 
procedure of PCR is as follows: denaturation (30 seconds at 98°C), 
followed by 27 cycles consisting of denaturation (15 seconds at 
98°C), annealing (15 seconds at 58°C), extension (15 seconds at 
72°C) and a final extension at 72°C for 1 minutes. PCR products 
were detected by 1% agarose gel electrophoresis. The magnetic 
bead system was used to purify the replicate PCR reactions. 
Purified PCR amplicons of each sample were mixed, according to 
the amplicon concentration of samples detected by Nanodrop. 
The amplicons were sequenced in a single pool in one run with 
the MiSeq platform (250 PE, Illumina), generating approximately 





(n = 50) χ2/t P
Age (y) 18.96 ± 0.64 19.00 ± 0.73 −0.29a .77
Gender, male (%) 11 (22) 10 (20) 0.06b .81
BMI (kg/m2) 22.03 ± 2.72 21.67 ± 3.03 0.62a .53
WHR 0.77 ± 0.05 0.77 ± 0.05 0.41a .68
Sleeping time (h) 7.21 ± 1.20 6.92 ± 1.48 −1.06a .29
Physical activity, n (%)   3.58b .17
Inactive 1 (2) 4 (8)   
Moderately 15 (30) 20 (40)   
Very active 34 (68) 26 (52)   
Family income, n (%)   0.56b .75
≤¥3000 22 (44) 21 (42)   
¥3001-5000 19 (38) 17 (34)   
≥¥5001 9 (18) 12 (24)   
No smoking, n (%) 50 (100) 49 (98) 1.01b .31
No drinking, n (%) 50 (100) 50 (100) – –
SBP (mm Hg) 120.90 ± 11.51 118.30 ± 12.54 1.06a .29
DBP (mm Hg) 77.18 ± 8.06 75.71 ± 10.80 0.77a .45
ALT (μg/L) 15.58 ± 9.14 15.48 ± 8.54 0.06a .96
AST (μg/L) 21.84 ± 5.63 22.38 ± 5.91 −0.46a .65
CKMB (μg/L) 9.26 ± 2.63 7.18 ± 4.46 0.11a .91
ALP (μg/L) 62.17 ± 15.27 62.76 ± 18.20 −0.17a .86
TBIL (μg/L) 15.60 ± 6.69 14.07 ± 5.89 1.19a .24
LDH (μg/L) 147.40 ± 23.08 142.70 ± 21.96 1.02a .31
Total score of 
SHSQ-25
17.58 ± 8.09 42.88 ± 7.24 −16.48a <.0001
Fatigue score 7.16 ± 3.48 16.70 ± 2.88 −14.92a <.0001
Cardiovascular 
system score
0.44 ± 0.88 3.42 ± 2.15 −9.07a <.0001
Digestive tract 
score
1.72 ± 1.55 4.50 ± 1.99 −7.78a <.0001
Immune system 
score
2.68 ± 1.43 5.08 ± 1.60 −7.89a <.0001
Mental status score 5.58 ± 3.41 13.18 ± 4.20 −9.94a <.0001
Abbreviations: ¥, Chinese Yuan; ALP, alkaline phosphatase; ALT, alanine aminotransferase; 
AST, aspartate aminotransferase; BMI, body mass index; CKMB, creatine kinase isoenzymes; 
DBP, diastolic blood pressure; LDH, lactate dehydrogenase; SBP, systolic blood pressure; SHS, 
suboptimal health status; SHSQ-25, Suboptimal Health Status Questionnaire-25; TBIL, total 
bilirubin; WHR, waist-to-hip ratio.
#Continuous variables were expressed as mean ± standard deviation, while discrete variables were 
represented as number (proportion); a, t value; b, χ2 value. 
TA B L E  1   Characteristics of subjects in 
SHS and healthy groups
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concatenate forward and reverse reads, paired-end sequences 
and barcodes were sorted and matched.
2.4 | Bioinformatic analysis
Quality filtering and analyses of microbial community diversity were 
performed with the QIIME1 software package (Quantitative Insights 
into Microbial Ecology). Sequences were removed from the analysis 
if they were <200 nt, had a quality score <20, contained ambiguous 
characters, contained an uncorrectable barcode or did not contain 
the primer sequence. Sequences were assigned to samples by exam-
ining their individual 12-nt barcode. Sequences were aligned through 
PyNAST and clustered into OTUs by 97% similarity, while taxonomy 
was assigned using the Ribosomal Database Project as a reference 
base. The phylogenetic tree was built with FastTree. QIIME1 and 
UniFrac were used for analyses of bacterial communities and group 
comparisons. Alpha diversity (Chao1 index, Shannon index, Simpson 
index and phylogenetic diversity index) was calculated in QIIME1. 
Across all specimens, the beta diversity distance metrics, including 
unweighted and weighted UniFrac distance metrics, were calculated 
and visualized by principal coordinates analysis (PCoA). To find fea-
tures differentially represented between healthy and SHS groups, 
linear discriminant effect size analysis (LEfSe)30 based on OTU level 
was performed. LEfSe, an algorithm for high-dimensional biomarker 
discovery, used linear discriminant analysis (LDA) to estimate the ef-
fect size of each taxon differentially represented in SHS and controls.
2.5 | Statistical analysis
The Kolmogorov-Smirnov test was used for normality test. If the data 
conformed to a normal distribution, continuous variables were pre-
sented as the mean ± standard deviation (SD), and an independent t 
test was used for analysis. If data were not normally distributed, con-
tinuous variables were presented as a median (interquartile range) and 
analysed by Wilcoxon rank-sum test. The χ2 test was used to examine 
differences in categorical variables between the cases and controls. 
Wilcoxon rank-sum tests were used to assess associations of individ-
ual taxon relative abundances. Alpha diversity was compared across 
groups by Wilcoxon rank-sum tests. In order to evaluate the discrimi-
native capability of intestinal microbiota, a random forest model was 
established using 10-fold cross-validation, and the performance of the 
random forest tree model was measured as the area under the curve 
(AUC). We firstly selected variables using stepwise method in the lo-
gistic regression and then selected variables which are statistically dif-
fered in the SHS and controls. Finally, these variables were entered 
into random forest model under full factory design, and the model with 
highest AUC value was selected as the best model.
All results were deemed significant if the P-value was below .05. 
The data analysis was performed using IBM SPSS Statistics software 
(version 20.0 from Armonk, NY: IBM Corp) and R software version 
3.4.2.
2.6 | Ethics statement
This study was approved by the ethics committee of Capital Medical 
University, Beijing, China. All subjects gave written informed con-
sent in accordance with the Declaration of Helsinki.
3  | RESULTS
3.1 | Demographic profiles of SHS and the controls
In total, 50 SHS individuals consisting of 40 female and 10 male partici-
pants with an average age of 19.00 ± 0.73 years, and 50 healthy stu-
dents with similar demographic features, composed of 39 female and 
11 male individuals with an average age of 18.96 ± 0.64 years, were se-
lected in the final analysis. The SHSQ-25 score of the SHS and control 
group was 42.88 ± 7.24 and 17.58 ± 8.09, respectively (P < .0001). Five 
dimensions of SHS were significantly different between the healthy 
and SHS groups (cardiovascular system: 0.44 ± 0.88 vs 3.42 ± 2.15, 
fatigue: 7.16 ± 3.48 vs 16.7 ± 2.88, digestive tract: 1.72 ± 1.55 vs 
4.5 ± 1.99, immune system: 2.68 ± 1.43 vs 5.08 ± 1.6, mental status: 
5.58 ± 3.41 vs 13.18 ± 4.2; all P < .0001, Table 1). A cluster analysis 
was used to describe SHSQ-25 for all individuals. The SHS and healthy 
samples can be clustered separately in different parts, and the cluster 
tree was shown in Figure S1. There were no significant differences be-
tween the SHS and control groups in demographic variables (age, sex, 
family income, alcohol consumption, smoking history and physical ac-
tivity), anthropometric measurements (BMI and WHR), blood pressure 
or biochemical measurements (Table 1).
3.2 | Microbial diversity
A total of 16 860 320 16S rRNA reads were obtained from the 100 
samples, with an average of 168 603 ± 97 006 reads per sample. 
After the quality filtering, 15 778 975 16S rRNA reads remained, 
with an average of 157 790 ± 85 638 reads per sample. The num-
ber of sequences in the smaller sample is 29 154 reads which was 
used to compensate for differential sequencing depth. Sequences 
were classified into 764 ± 204 operational taxonomic units (OTUs) 
per sample at the identity threshold of 97%, and 1.64% reads were 
not clustered as OTU (Figure S2). The sequence-based rarefaction 
curves based on the observed species were nearly asymptotic 
(Figure 1A). SHS individuals had higher microbial diversity com-
pared with that of healthy individuals (Simpson index: Median 0.92 
(P25-P75: 0.87-0.94) vs 0.90 (0.83-0.93), P = .048; Shannon: 4.83 
(4.25-5.26) vs 4.61 (3.64-4.99), P = .042). There is no difference 
in microbial richness indices between SHS individuals and con-
trols (observed species: median 757.00 (P25-P75: 632.50-882.50) 
vs 785.50 (602.5-878.75), P = .931; phylogenetic diversity: 23.50 
(20.27-27.59) vs 23.61 (17.71-27.68), P = .815; Chao1: 1011.89 
(871.22-1176.25) vs 1037.91 (817.12-1153.75), P = .978; Figure 1, 
Table S3).
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Weighted and unweighted UniFrac distance metric matrices 
were used to evaluate overall differences between the two groups 
through PCoA. Weighted UniFrac distance metrics in some extent 
distinguished the intestinal microbiota of SHS subjects from that of 
the control subjects (P = .018). There appeared to be a difference in 
beta diversity between the SHS group and healthy group (Figure 2). 
On the weighted UniFrac distance metrics figure, there is a cluster 
of nine healthy and one SHS at the top right corner that is clearly 
separated from the rest of the individuals. The aspartate amino-
transferase (AST) and alanine aminotransferase (ALT) were found to 
be increased in the 10 individuals (Table S4). In order to find the re-
lationship between ALT/AST and intestinal microbiota, a Spearman's 
correlation analysis was performed. In phylum level, ALT had a weak 
positive correlation with Euryarchaeota (r = .28, P = .01), and AST 
had weak positive correlation with Actinobacteria (r = .26, P = .01) 
and Synergistetes (r = .23, P = .03; Table S5).
3.3 | Composition of faecal bacteria
At the phylum level, the majority of the 16S reads were classi-
fied into four phyla: Firmicutes (52.92%), Bacteroidetes (33.41%), 
Proteobacteria (9.99%) and Actinobacteria (2.44%). The two larg-
est phyla represented in each dataset of controls and SHS groups 
were Firmicutes and Bacteroidetes (Figure 3). Verrucomicrobia, 
Fusobacteria, Tenericutes, Euryarchaeota, TM7, Cyanobacteria 
F I G U R E  1   Rarefaction curves and 
comparison of alpha diversity between 
the gut microbiota of SHS and controls 
(50 cases & 50 controls). Rarefaction 
curves for the observed species of healthy 
individuals and SHS individuals (A). Five 
indices were used to represent the alpha 
diversity, which is Observed species (B), 
Simpson index (C), PD whole tree (D), 
Chao1 index (E) and Shannon index (F). PD 
indicates phylogenetic diversity
F I G U R E  2   Principal coordinate 
analysis illustrating the grouping patterns 
of the SHS and control individuals based 
on the unweighted UniFrac (A) (P = .145) 
and weighted UniFrac (B) distances (50 
cases & 50 controls, P = .018)
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and Synergistetes were also detected, representing 1% of the total 
reads analysed. At the phylum level, the relative abundance of 
Verrucomicrobia was considered to be higher in the SHS group than 
in the controls (P = .049; Table S6). There was no significant differ-
ence in ratio of Firmicutes/Bacteroidetes between SHS and control 
group (P = .11, Table S6).
At the genus level, 352 different bacterial genera were identi-
fied from SHS and controls in the study. The genera represented 
in almost all subjects were Bacteroides (19.52%), Faecalibacterium 
(15.25), Prevotella (10.21%), Escherichia (5.52%), Dialister (4.82%), 
Roseburia (4.03%) and Ruminococcus (3.5%). In SHS group, the com-
parative abundances of Oscillospira, Pseudobutyrivibrio, Roseburia, 
F I G U R E  3   Composition of the 
intestinal microbiota of healthy individuals 
and SHS patients in phylum level (A) and 
family-level (B) gut microbial taxa (50 
cases & 50 controls)
F I G U R E  4   Phylogenetic dendrogram 
of biomarker bacteria between SHS and 
control groups (50 cases & 50 controls)
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Ruminococcus, Chryseobacterium, unclassified Clostridiaceae, 
unclassified Rikenellaceae, unclassified Fusobacteriaceae and 
unclassified Peptococcaceae were higher, while the relative abun-
dances of Clostridiaceae 02d06, Sutterella, Ralstonia, Morganella 
and unclassified Peptococcaceae were lower compared with those 
of the healthy group. (P < .05, Table S6; Figure S3). LEfSe analysis, 
an algorithm for high-dimensional biomarker discovery, further 
confirms these significant differences. Twenty-four discriminative 
features (LDA score ≥2) with relative abundances varied signifi-
cantly between the SHS group and the control group (Figures 4 
and 5). Taxon annotation of OTUs from all samples was shown in 
Table S7.
3.4 | Using a random forest model to discriminate 
between the SHS group and the control group
A random forest approach was used to classify samples into SHS or 
control groups. The random forest diagnosis model was validated by 
10-fold cross-validation. The AUC for the random forest diagnostic 
model of SHS was 0.79 (95% CI: 0.77-0.81; Figure 6). The confusion 
matrix of the model is shown in Table 2.
4  | DISCUSSION
In the present study, alpha diversity of intestinal microbiota in SHS 
individuals was significantly higher compared with that of healthy 
controls. In addition, beta diversity was significantly different be-
tween SHS and healthy controls, but the difference is not big 
enough. Sixteen intestinal bacterial biomarkers of SHS were iden-
tified by LEfSe analysis. The intestinal microbiota can effectively 
discriminate individuals with SHS from the controls, with an AUC 
of 0.79 (95% CI: 0.77-0.81). This is the first attempt to explore the 
association between SHS and intestinal microbiota.
Alpha diversity, the mean species diversity of habitats at a local 
scale, includes two levels: richness and evenness.31 Kostic et al32 
reported that microbial richness and the diversity of individuals de-
creased before the onset of type 1 diabetes. Li et al21 and Yan et al33 
showed that the microbial richness and diversity of patients with hy-
pertension were dramatically decreased. In the present study, there 
is no difference of the microbial richness (Chao1 index, observed 
species and phylogenetic diversity) between SHS individuals and 
healthy controls. However, the Simpson index and Shannon index, 
a comprehensive indicator of richness and evenness, in SHS indi-
viduals were higher than that of controls, suggesting that microbial 
diversity of SHS is higher than that of controls. The phenomenon of 
microbial diversity decreasing in disease status but increasing in SHS 
remains a mystery. The strict exclusion criteria in the definition of 
SHS and ideal health status, together with the homogeneity of youth 
undergraduates, might partly explain these disparities. Additionally, 
we showed that the beta diversity, determined by weighted UniFrac 
distance metrics, can significantly discriminate SHS subjects from 
control subjects, suggesting that changed diversity of intestinal mi-
crobiota occurs in SHS before the onset of NCDs. In the Figure 2B, 
10 individuals (nine controls and one SHS) were clearly separated 
from other individuals. The AST and ALT of these 10 individuals were 
within normal range, but significantly higher than those of remains, 
might suggesting that there is an association between intestinal mi-
crobiota and transaminases. In phylum level, ALT had a weak positive 
correlation with Euryarchaeota, and AST had weak positive correla-
tion with Actinobacteria and Synergistetes. Euryarchaeota, belong 
to archaea, is mainly composed of methanogenic bacteria which 
indirectly affects the health of the human body.34 Abundance of 
F I G U R E  5   Linear Discriminant 
Analysis (LDA) score of LEfSe analysis 
between SHS and control groups (50 
cases & 50 controls, LDA score ≥2)
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Actinobacteria increased in acute-on-chronic alcohol mice while de-
creased in cirrhotic patients.35,36 Increased Synergistetes was found 
in bile from individuals with opisthorchiasis.37 As mentioned above, 
these bacterial abundances are altered in several diseases, but it is 
difficult to clarify how these bacteria affect the level of ALT/AST.
Alterations of intestinal microbiota composition are suspected 
to affect the host inflammatory and metabolic responses, and 
several studies have shown that disruption of intestinal microbi-
ota equilibrium was associated with chronic diseases.38-41 In our 
study, the large majority of all sequences identified belonged to 
one of four phyla, Firmicutes, Bacteroidetes, Proteobacteria or 
Actinobacteria, consistent with previous reports from human in-
testinal microbiota studies.42 However, the relative proportions 
of Verrucomicrobia were significantly higher in SHS individuals 
than in healthy controls. Previous study found that the relative 
proportions of Verrucomicrobia increased in the intestine follow-
ing broad-spectrum antibiotic treatment.43 This difference may be 
attributed to a medication history of antibiotic use. Participants 
with SHS are susceptible to diseases, and they have poor resis-
tance to disease. Therefore, the frequency of antibiotic consump-
tion might be higher than those of healthy. Although participants 
have a history of antibiotic consumption in the previous 2 months 
were excluded, participates used antibiotic before 2 months might 
affect the intestinal microbiota. In another study, the abundance 
of Verrucomicrobia was found to be modulated by the immune 
system,44 and the immune system is a component of SHS, sug-
gesting SHS leads to inflammation which causes changes in intes-
tinal microbiota. In our study, five genera, including Oscillospira, 
Pseudobutyrivibrio, Roseburia, Ruminococcus and Chryseobacterium, 
were increased compared with those in controls. Konikoff et al re-
ported that Oscillospira is associated with lower BMI and inflam-
matory diseases and Oscillospira may utilize mammalian-derived 
glycans from host or animal protein-rich diet.45 Some Oscillospira 
species can probably produce the important short-chain fatty acid 
butyrate which is important for prevention of inflammation.46,47 A 
recent study showed that the relative abundance of Oscillospira is 
increased in patients with gallstones compared with that of con-
trols.48 The mechanism of cholesterol gallstone disease is associ-
ated with inflammation,49 suggesting that changes in Oscillospira 
may be associated with inflammation. Ruminococcus, a member of 
the family Ruminococcaceae, has been reported to increase in col-
orectal cancer,50 Alzheimer's disease51 and type 1 diabetes,52 but 
decreased in Crohn's disease.53,54 Ruminococcus is a butyrate-pro-
ducing bacterium, and butyrate has a positive effect on human 
health through anti-inflammatory effects. In this study, we ob-
served that Ruminococcus decrease in SHS, and this inconsistence 
remains unexplainable. Increased Pseudobutyrivibrio and Roseburia 
have been observed in patients with acute diverticulitis55 and 
Hashimoto's thyroiditis,56 respectively. Chryseobacterium, a 
gram-negative bacterium, causes endogenous infection due to low 
host immunity and the irrational use of antibiotics.57 In addition, 
SHS individuals were also characterized by a significant reduc-
tion in Clostridiaceae 02d06, Sutterella, Ralstonia and Morganella. 
Clostridiaceae 02d06 was enriched in T2DM patients compared 
with that in individuals without diabetes.58 Decreased abundance 
of Sutterella and Ralstonia were observed in patients with ulcer-
ative colitis (UC)40 and atherosclerosis,59 respectively. Sutterella 
is considered to be a microorganism that induces a protective 
immune regulation profile.60 The above discussion suggests that 
alterations of intestinal microbiota in the SHS may involve diet 
and inflammation. In the LEfSe analysis, the relative abundances 
of Ruminococcaceae, Oscillospira, Rikenellaceae, Verrucomicrobia, 
Order YS2 [cyanobacteria], Roseburia, Chryseobacterium, Class 
4C0d-2 [cyanobacteria], Peptococcaceae and Ruminococcuswere 
higher in SHS individuals than in the controls, indicating that bac-
teria could be potential biomarkers for SHS.
Several diseases can be diagnosed using intestinal microbiota. 
Faecal microbiota can be used to discriminate Parkinson's disease 
patients from controls with an AUC of 0.81 (95% CI: 0.72-0.90), 
a sensitivity of 75.60% and a specificity of 77.80%.61 The intesti-
nal microbiota was also used for the diagnosis of hypertension 
(AUC = 0.91, 95% CI: 0.75-1.00)21 and early hepatocellular carci-
noma (AUC = 0.81, 95% CI: 0.74-0.87).62 Additionally, the micro-
biome was used for the diagnosis of several diseases, including 
CFS (AUC = 0.89)28 and ileal Crohn's disease (AUC = 0.97).39 In the 
present study, we also performed a supervised random forest tree 
(RF) model to diagnose SHS, resulting in an AUC (0.79, 95% CI: 0.77-
0.81). Recently, we demonstrated that plasma adrenaline/noradren-
aline and cortisol can be used to diagnose SHS, with AUC values 
F I G U R E  6   Receiver operating characteristic (ROC) curve 
analysis of random forest analysis in the diagnosis of SHS
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of 0.69 (95% CI: 0.65-0.73) and 0.91 (95% CI: 0.89-0.93), respec-
tively.63 Therefore, the combination of intestinal microbiota and 
serum biochemicals, such as plasma adrenaline/noradrenaline and 
cortisol, might increase the capability of diagnosis using objective 
biomarkers.
The aetiology of SHS remains unclear; however, stress re-
sponses,7 which can trigger inflammation,64 are the primarily 
recognized mechanism. We previously demonstrated that SHS is as-
sociated with mRNA expression of glucocorticoid receptors in lym-
phocytes, which has been implicated in inflammatory responses.11 
Increasing evidence has demonstrated that the disturbance of the 
intestinal microbiota can lead to systemic inflammation.65 In addi-
tion, different intestinal microbiota between the healthy and SHS 
individuals were identified in terms of the relative abundance of 
specific genera. Given these findings, abnormalities in intestinal mi-
crobiota might shape chronic inflammation in the gut, which subse-
quently leads to SHS. It highlights the association of specific taxa 
with SHS, and the identification of the underlying role of this altered 
commensal intestinal microbiota could supply novel diagnostic or 
therapeutic strategies.
There are several limitations in our study that may influence the 
results. First, in this study, we included more females than males, 
which might introduce selection bias in the association between 
intestinal microbiota and SHS. The prevalence of SHS is higher in 
females than that in males, and the response rate in faecal sample 
collection is also higher in females than in males. To increase the 
comparability between groups, we matched SHS cases and controls 
using propensity score matching based on age, gender and BMI. 
Second, the design of a case-control study based on a cross-sec-
tional study makes it inevitable to avoid selection bias and may 
overestimate the accuracy of diagnosis for SHS. Third, the diet of 
participants, the main associated factor of the intestinal microbi-
ota,66 was not controlled, which might introduce confounding bias. 
Forth, the cortisol and adrenaline/noradrenaline, the only known 
measurable biochemical parameter of SHS, were not included in our 
study. Finally, the sample size of our study is relatively small, result-
ing in the absence of statistical power. Therefore, further cohort 
studies with larger sample sizes are needed to explore the causal 
association between SHS and the intestinal microbiota.
5  | CONCLUSION
In this case-control study with a relatively small sample size, we first 
demonstrated that the intestinal microbiota is associated with SHS. 
Alteration of intestinal microbiota occurs with SHS, an early stage 
of disease, which might shed light on the importance of intestinal 
microbiota in the primary prevention of NCDs.
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